NICE asks Janssen to put leukemia drug forward for new Cancer Drugs Fund
UK medicines cost-effectiveness watchdog the National Institute for Health and Care Excellence (NICE) has asked Janssen, to set out a case for including its leukemia drug Imbruvica (ibrutinib) in the Cancer Drugs Fund (CDF).
This should come as a positive surprise for Janssen, a subsidiary of US health care giant Johnson & Johnson (NYSE: JNJ), which earlier this year received a negative opinion from the NICE, declining to recommend use of the drug for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) who are not suitable for chemo-immunotherapy.
Up to 1 in 10 adults with chronic lymphocytic leukemia (CLL) have a form of cancer with genetic changes that make their disease progress quicker and more difficult to treat. The treatment options for CLL with these genetic changes (known as 17p deletion or TP53 mutation) are very limited, according to the NICE.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze